Canaccord Genuity Upgrades Biogen to Buy, Announces $360 Price Target

Canaccord Genuity analyst Sumant Kulkarni upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $360 price target.

Benzinga · 01/27/2020 11:00

Canaccord Genuity analyst Sumant Kulkarni upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $360 price target.